TIMELINE OF LEGAL ACTIONS AGAINST ANTIPSYCHOTIC MANUFACTURERS: ELI LILLY & CO., Bristol-Myers Squibb, JANSSEN & ASTRAZENECA
March 2007
Published information shows that 8 states have filed lawsuits against antipsychotic drug manufacturers: Alaska, Louisiana, Mississippi, Montana, New Mexico, Pennsylvania, Texas and West Virginia.
Four more states have subpoenaed Eli Lilly & Co. for documents related to the marketing of its antipsychotic drug Zyprexa: California, Florida, Illinois and Vermont.
Massachusetts and Oregon are also investigating Eli Lilly & Co. over Zyprexa.
2001: August: At a meeting of the American Psychiatric Association, Dr. Frank J. Ayd, the psychopharmacologist that helped develop neuroleptics in the 1950s and 60s, presented findings of his review of literature for atypical antipsychotics. He determined that there was a “startling” association between initiation of treatment with olanzepine (Zyprexa) and new-onset of diabetes in adolescents.
November: Researchers at the FDA’s Center for Drug Evaluation and Dr. P. Maurali Doraisewamy of Duke University confirmed Dr. Ayd’s findings. Both found a causal association between Eli Lilly & Co.’s Zyprexa and diabetes—10 times higher than in the general population.[ii]
2003: April: Officials at Johnson & Johnson announced plans to send letters to U.S. physicians to warn them of the potential increased risk of stroke for elderly patients who take the antipsychotic drug Risperdal. This was similar to that issued to Canadian doctors in October 2002.[iii]
September: The FDA requested the makers of six atypical antipsychotic drugs to add a caution to their labeling language about the potential risk of diabetes and blood sugar abnormalities.[iv]
2004: January: Eli Lilly & Co. announced it had warned doctors of using Zyprexa among elderly patients with dementia. A letter issued on January 15 warned of increased risks of death and stroke when elderly patients with dementia were prescribed Zyprexa.[v]
March: The U.S. Attorney for Pennsylvania began a civil investigation into Eli Lilly & Co.’s marketing and promotional practices of Zyprexa, Prozac and Evista (an osteoporosis medicine).[vi]
April 19: The filing of the first nationwide Zyprexa class action lawsuit was announced, linking the drug to diabetes, hyperglycemia and pancreatitis.[vii]
June: The Australian Therapeutic Goods Administration published an Adverse Drug Reactions Bulletin warning that the newest antipsychotics could increase the risk of diabetes.[viii]
February: The American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists and the North American Association for the Study of Obesity issued a consensus statement regarding diabetes risk with the use of atypical antipsychotics.[ix]
[
link to www.docstoc.com]
Last Edited by Account Deleted by User on 02/09/2012 03:40 PMYour VILLAGE called, their IDIOT is missing.
Your IDIOT called, their VILLAGE is missing.